fbpx Skip to main content

Member's Profile

Viracta Therapeutics

2533 S Coast Highway 101 Ste 210
Cardiff,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2017
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Viracta Therapeutics
Biotech Company
Viracta is advancing a proprietary viral gene activation therapy to address viral-associated cancers and other serious disease. 
Viracta’s treatment approach combines inhibition of selected histone deacetylases (HDACs) to trigger activation of herpes virus family’s thymidine kinase to enable conversion of orally administered antiviral pro-drug, valganciclovir, to its active cytotoxic form as a targeted therapy to selectively eradicate cancer cells harboring the virus. To pursue this opportunity, Viracta is advancing its drug candidate, VRx-3996, with best-in-class properties for the viral activation approach into Phase 2 clinical trials for Epstein-Barr Virus (EBV)-associated lymphomas, and will pursue additional applications to treat viral associated cancers and other serious diseases.
Related News
No related news posted by this Member